Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-01

AUTHORS

Claus Rödel, Jürgen Dunst, Gerhard G. Grabenbauer, Reinhard Kühn, Thomas Papadopoulos, Karl Michael Schrott, Rolf Sauer

ABSTRACT

PURPOSE: Current treatment options for high-risk superficial T1-bladder cancer (Grade 3, associated Tis, multifocality, tumor diameter > 5 cm or multiple recurrences) include early cystectomy or the goal of organ preservation by adjuvant intravesical therapy after transurethral resection (TURB). We have evaluated the efficacy of adjuvant radiotherapy or radiochemotherapy on local control, bladder preservation, recurrence rate and long-term survival after TURB of high-risk T1-bladder cancer. PATIENTS AND METHODS: From May 1982 to May 1999, a total of 74 patients with T1-bladder cancer were treated by either radiotherapy (n = 17) or concomitant radiochemotherapy (n = 57) after TURB. Radiotherapy was initiated 4 to 8 weeks after TURB; a median dose of 54 (range: 45 to 60) Gy was applied to the bladder with daily fractions of 1.8 to 2.0 Gy. Since 1985 chemotherapy has been given in the 1st and 5th week of radiotherapy and consisted of cisplatin (25 mg/m2/d) in 33 patients, carboplatin (65 mg/m2/d) was administered in 14 patients with decreased creatine clearance (< 50 ml/min). Since 1993 a combination of cisplatin (20 mg/m2/d) and 5-fluorouracil (600 mg/m2/d) was applied to 10 patients. Salvage cystectomy was recommended for patients with refractory disease or invasive recurrences. At the time of analysis, the median follow-up for surviving patients was 57 (range: 3 to 174) months. RESULTS: After radiotherapy/radiochemotherapy, a complete remission at restaging TURB was achieved in 62 patients (83.7%), 35 of whom (47% with regard to the total cohort of the 74 treated patients) have been continuously free of tumor, 11 patients (18%) experienced a superficial relapse and 16 patients (26%) showed tumor progression after initial complete response. Overall-survival was 72% at 5 years and 50% at 10 years with 77% of the surviving patients maintaining their own bladder at 5 years. Negative prognostic factors for cancer-specific survival were non-complete (R1/2) initial TURB (p = 0.12) and recurrent disease (p = 0.07); combined radiochemotherapy was more effective than radiotherapy alone (p = 0.1). CONCLUSION: Adjuvant radiotherapy/radiochemotherapy offers an additional option in high-risk superficial bladder cancer with a high chance of cure and bladder preservation. The ultimate value of radiotherapy in comparison with other treatment options should be determined in randomized trials. More... »

PAGES

82-88

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/pl00002387

DOI

http://dx.doi.org/10.1007/pl00002387

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025911325

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11233839


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carboplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cystectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy Dosage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Radiation Oncology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00f6del", 
        "givenName": "Claus", 
        "id": "sg:person.01110566562.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110566562.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Martin Luther University Halle-Wittenberg", 
          "id": "https://www.grid.ac/institutes/grid.9018.0", 
          "name": [
            "Department of Radiation Oncology, University of Halle, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dunst", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.01013257674.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013257674.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Radiation Oncology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grabenbauer", 
        "givenName": "Gerhard G.", 
        "id": "sg:person.01316171657.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316171657.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Urology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fchn", 
        "givenName": "Reinhard", 
        "id": "sg:person.014202704312.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014202704312.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Pathology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papadopoulos", 
        "givenName": "Thomas", 
        "id": "sg:person.0621421301.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621421301.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Urology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schrott", 
        "givenName": "Karl Michael", 
        "id": "sg:person.01051147475.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051147475.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Erlangen-Nuremberg", 
          "id": "https://www.grid.ac/institutes/grid.5330.5", 
          "name": [
            "Department of Radiation Oncology, University of Erlangen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sauer", 
        "givenName": "Rolf", 
        "id": "sg:person.0722130722.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722130722.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1997.00431.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008241807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1997.00431.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008241807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1997.00431.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008241807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)68208-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013140297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)68208-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013140297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)67321-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014467598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02742341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014516874", 
          "https://doi.org/10.1007/bf02742341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02742341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014516874", 
          "https://doi.org/10.1007/bf02742341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(94)90113-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018946764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(94)90003-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019330456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)66692-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021146825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)68645-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021384730"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1996.08486.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031490175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(97)00579-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032625558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)65673-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036005084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)65458-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047312681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(98)00013-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053656241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.1.53", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059817898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(17)36724-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076835047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(17)37241-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077377706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000472824", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079740078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1995.13.6.1404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082492504"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.11.2150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082711800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.11.2901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082998128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.1022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057217"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-01", 
    "datePublishedReg": "2001-01-01", 
    "description": "PURPOSE: Current treatment options for high-risk superficial T1-bladder cancer (Grade 3, associated Tis, multifocality, tumor diameter > 5 cm or multiple recurrences) include early cystectomy or the goal of organ preservation by adjuvant intravesical therapy after transurethral resection (TURB). We have evaluated the efficacy of adjuvant radiotherapy or radiochemotherapy on local control, bladder preservation, recurrence rate and long-term survival after TURB of high-risk T1-bladder cancer.\nPATIENTS AND METHODS: From May 1982 to May 1999, a total of 74 patients with T1-bladder cancer were treated by either radiotherapy (n = 17) or concomitant radiochemotherapy (n = 57) after TURB. Radiotherapy was initiated 4 to 8 weeks after TURB; a median dose of 54 (range: 45 to 60) Gy was applied to the bladder with daily fractions of 1.8 to 2.0 Gy. Since 1985 chemotherapy has been given in the 1st and 5th week of radiotherapy and consisted of cisplatin (25 mg/m2/d) in 33 patients, carboplatin (65 mg/m2/d) was administered in 14 patients with decreased creatine clearance (< 50 ml/min). Since 1993 a combination of cisplatin (20 mg/m2/d) and 5-fluorouracil (600 mg/m2/d) was applied to 10 patients. Salvage cystectomy was recommended for patients with refractory disease or invasive recurrences. At the time of analysis, the median follow-up for surviving patients was 57 (range: 3 to 174) months.\nRESULTS: After radiotherapy/radiochemotherapy, a complete remission at restaging TURB was achieved in 62 patients (83.7%), 35 of whom (47% with regard to the total cohort of the 74 treated patients) have been continuously free of tumor, 11 patients (18%) experienced a superficial relapse and 16 patients (26%) showed tumor progression after initial complete response. Overall-survival was 72% at 5 years and 50% at 10 years with 77% of the surviving patients maintaining their own bladder at 5 years. Negative prognostic factors for cancer-specific survival were non-complete (R1/2) initial TURB (p = 0.12) and recurrent disease (p = 0.07); combined radiochemotherapy was more effective than radiotherapy alone (p = 0.1).\nCONCLUSION: Adjuvant radiotherapy/radiochemotherapy offers an additional option in high-risk superficial bladder cancer with a high chance of cure and bladder preservation. The ultimate value of radiotherapy in comparison with other treatment options should be determined in randomized trials.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/pl00002387", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054450", 
        "issn": [
          "0179-7158", 
          "1439-099X"
        ], 
        "name": "Strahlentherapie und Onkologie", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "177"
      }
    ], 
    "name": "Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer", 
    "pagination": "82-88", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7b71618aabc9756923518a225f9aad95c9ff4f2e51e5fb8380b17a49e5509147"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11233839"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8603469"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/pl00002387"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025911325"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/pl00002387", 
      "https://app.dimensions.ai/details/publication/pub.1025911325"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FPL00002387"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/pl00002387'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/pl00002387'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/pl00002387'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/pl00002387'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      21 PREDICATES      77 URIs      48 LITERALS      36 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/pl00002387 schema:about N017243157bd247a9995ec69d2e22d14a
2 N06218f3deca8437bbc6acfa843a34a29
3 N20baee4a44d44472ae5b2c7e72299f09
4 N332422de91bf49acb6974ce1c9535a93
5 N4bf5a3a723d5463eb18f30a9c702faad
6 N4c6a5b1966c4451a826a2e2811590d85
7 N59357d0d7c9f4d28806153864e94eb2b
8 N5a1c97f4bcd24786bc21e0ce5ba3bdf3
9 N5d7d71591a9d4687a021c8b7ecb4097b
10 N5d82867814ce4faaab8125cb8171c44c
11 N61398b07cb964e6da6da78ef6717a083
12 N7f14ed3eafc94351a4bd88f8f576b7e9
13 N8165501f1a3f4fa487f44226a04c75fe
14 N8e4c6e9de7554d09b4f93a55177ad737
15 N9b530e492a13419f87e6cef1b5fa1da3
16 Na45ad12eab9044159941b67c78712496
17 Nb2d3e1319712438699e360f1f3e585c7
18 Nb45bbcb737a040028b8456467e92e7b1
19 Nb5c97ee5122c44969c39071c10cb80f8
20 Nc9399ad543b94db0ac83399e7f2a6aad
21 Ncaae9ad919e2419d8894824462b4756b
22 Ncaf94963d6e740b1b8c73656ce426a33
23 Ncd3ed2a5724845bdbc7de1d86ea49297
24 Ne531c7481bf144b8bf8c968377fa10d7
25 Ne6ba15ef6a0d4ddba8ce6bcb3469a26d
26 Nec9bd765c6a04a23b7de073bd7343a10
27 Nfcfa0d2443f447c283b6c8220ba91249
28 anzsrc-for:11
29 anzsrc-for:1112
30 schema:author N22127d8b2ef248849887746d8f64d296
31 schema:citation sg:pub.10.1007/bf02742341
32 https://doi.org/10.1016/0360-3016(94)90003-5
33 https://doi.org/10.1016/0959-8049(94)90113-9
34 https://doi.org/10.1016/s0022-5347(01)65458-2
35 https://doi.org/10.1016/s0022-5347(01)65673-8
36 https://doi.org/10.1016/s0022-5347(01)66692-8
37 https://doi.org/10.1016/s0022-5347(01)67321-x
38 https://doi.org/10.1016/s0022-5347(05)68208-0
39 https://doi.org/10.1016/s0022-5347(05)68645-4
40 https://doi.org/10.1016/s0022-5347(17)36724-1
41 https://doi.org/10.1016/s0022-5347(17)37241-5
42 https://doi.org/10.1016/s0360-3016(97)00579-8
43 https://doi.org/10.1016/s0360-3016(98)00013-3
44 https://doi.org/10.1046/j.1464-410x.1996.08486.x
45 https://doi.org/10.1046/j.1464-410x.1997.00431.x
46 https://doi.org/10.1093/jnci/85.1.53
47 https://doi.org/10.1159/000472824
48 https://doi.org/10.1200/jco.1993.11.11.2150
49 https://doi.org/10.1200/jco.1995.13.6.1404
50 https://doi.org/10.1200/jco.1996.14.11.2901
51 https://doi.org/10.1200/jco.1997.15.3.1022
52 schema:datePublished 2001-01
53 schema:datePublishedReg 2001-01-01
54 schema:description PURPOSE: Current treatment options for high-risk superficial T1-bladder cancer (Grade 3, associated Tis, multifocality, tumor diameter > 5 cm or multiple recurrences) include early cystectomy or the goal of organ preservation by adjuvant intravesical therapy after transurethral resection (TURB). We have evaluated the efficacy of adjuvant radiotherapy or radiochemotherapy on local control, bladder preservation, recurrence rate and long-term survival after TURB of high-risk T1-bladder cancer. PATIENTS AND METHODS: From May 1982 to May 1999, a total of 74 patients with T1-bladder cancer were treated by either radiotherapy (n = 17) or concomitant radiochemotherapy (n = 57) after TURB. Radiotherapy was initiated 4 to 8 weeks after TURB; a median dose of 54 (range: 45 to 60) Gy was applied to the bladder with daily fractions of 1.8 to 2.0 Gy. Since 1985 chemotherapy has been given in the 1st and 5th week of radiotherapy and consisted of cisplatin (25 mg/m2/d) in 33 patients, carboplatin (65 mg/m2/d) was administered in 14 patients with decreased creatine clearance (< 50 ml/min). Since 1993 a combination of cisplatin (20 mg/m2/d) and 5-fluorouracil (600 mg/m2/d) was applied to 10 patients. Salvage cystectomy was recommended for patients with refractory disease or invasive recurrences. At the time of analysis, the median follow-up for surviving patients was 57 (range: 3 to 174) months. RESULTS: After radiotherapy/radiochemotherapy, a complete remission at restaging TURB was achieved in 62 patients (83.7%), 35 of whom (47% with regard to the total cohort of the 74 treated patients) have been continuously free of tumor, 11 patients (18%) experienced a superficial relapse and 16 patients (26%) showed tumor progression after initial complete response. Overall-survival was 72% at 5 years and 50% at 10 years with 77% of the surviving patients maintaining their own bladder at 5 years. Negative prognostic factors for cancer-specific survival were non-complete (R1/2) initial TURB (p = 0.12) and recurrent disease (p = 0.07); combined radiochemotherapy was more effective than radiotherapy alone (p = 0.1). CONCLUSION: Adjuvant radiotherapy/radiochemotherapy offers an additional option in high-risk superficial bladder cancer with a high chance of cure and bladder preservation. The ultimate value of radiotherapy in comparison with other treatment options should be determined in randomized trials.
55 schema:genre research_article
56 schema:inLanguage en
57 schema:isAccessibleForFree false
58 schema:isPartOf Ne86029b3c0204765b05b540ba1dfde9b
59 Nf552be9de9854b3a8f26462e3aab38fe
60 sg:journal.1054450
61 schema:name Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer
62 schema:pagination 82-88
63 schema:productId N1fc929bde1f94a08a7c3d07331f888ad
64 Nd1656ab55ed84f9ebc17ad2214b927f4
65 Nd167133647f347268b302118b18ca00d
66 Neb8a978c44e945549ee56e689b6504ab
67 Nfc777a5305b14aac93d4fe3e4989fd0a
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025911325
69 https://doi.org/10.1007/pl00002387
70 schema:sdDatePublished 2019-04-10T19:57
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher N594f6d52d9e94a3f9e71ac3642cf9de9
73 schema:url http://link.springer.com/10.1007%2FPL00002387
74 sgo:license sg:explorer/license/
75 sgo:sdDataset articles
76 rdf:type schema:ScholarlyArticle
77 N017243157bd247a9995ec69d2e22d14a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Urinary Bladder Neoplasms
79 rdf:type schema:DefinedTerm
80 N06218f3deca8437bbc6acfa843a34a29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Fluorouracil
82 rdf:type schema:DefinedTerm
83 N1fc929bde1f94a08a7c3d07331f888ad schema:name readcube_id
84 schema:value 7b71618aabc9756923518a225f9aad95c9ff4f2e51e5fb8380b17a49e5509147
85 rdf:type schema:PropertyValue
86 N20baee4a44d44472ae5b2c7e72299f09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Radiotherapy
88 rdf:type schema:DefinedTerm
89 N21720d890e944ce9bd254b05da898684 rdf:first sg:person.01051147475.66
90 rdf:rest N8b79e5fc1fdb4f23a82dbb8d9edb07da
91 N22127d8b2ef248849887746d8f64d296 rdf:first sg:person.01110566562.10
92 rdf:rest N9575606d794e4ddba2493c606618f2da
93 N332422de91bf49acb6974ce1c9535a93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Time Factors
95 rdf:type schema:DefinedTerm
96 N4bf5a3a723d5463eb18f30a9c702faad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Radiotherapy Dosage
98 rdf:type schema:DefinedTerm
99 N4c6a5b1966c4451a826a2e2811590d85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Carboplatin
101 rdf:type schema:DefinedTerm
102 N52b9be1eb3434f8d98eb9f840b05853c rdf:first sg:person.014202704312.23
103 rdf:rest N808751b0c6af4eb7a4e2da59f08bd154
104 N59357d0d7c9f4d28806153864e94eb2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Male
106 rdf:type schema:DefinedTerm
107 N594f6d52d9e94a3f9e71ac3642cf9de9 schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 N5a1c97f4bcd24786bc21e0ce5ba3bdf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Radiotherapy, Adjuvant
111 rdf:type schema:DefinedTerm
112 N5d7d71591a9d4687a021c8b7ecb4097b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Salvage Therapy
114 rdf:type schema:DefinedTerm
115 N5d82867814ce4faaab8125cb8171c44c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Combined Modality Therapy
117 rdf:type schema:DefinedTerm
118 N61398b07cb964e6da6da78ef6717a083 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Adult
120 rdf:type schema:DefinedTerm
121 N7f14ed3eafc94351a4bd88f8f576b7e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Cisplatin
123 rdf:type schema:DefinedTerm
124 N808751b0c6af4eb7a4e2da59f08bd154 rdf:first sg:person.0621421301.50
125 rdf:rest N21720d890e944ce9bd254b05da898684
126 N8165501f1a3f4fa487f44226a04c75fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Aged
128 rdf:type schema:DefinedTerm
129 N8b79e5fc1fdb4f23a82dbb8d9edb07da rdf:first sg:person.0722130722.52
130 rdf:rest rdf:nil
131 N8e4c6e9de7554d09b4f93a55177ad737 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Female
133 rdf:type schema:DefinedTerm
134 N9575606d794e4ddba2493c606618f2da rdf:first sg:person.01013257674.45
135 rdf:rest Nd946b48249b549738ecc10167360e6be
136 N9b530e492a13419f87e6cef1b5fa1da3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Age Factors
138 rdf:type schema:DefinedTerm
139 Na45ad12eab9044159941b67c78712496 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Chemotherapy, Adjuvant
141 rdf:type schema:DefinedTerm
142 Nb2d3e1319712438699e360f1f3e585c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Risk Factors
144 rdf:type schema:DefinedTerm
145 Nb45bbcb737a040028b8456467e92e7b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Cystectomy
147 rdf:type schema:DefinedTerm
148 Nb5c97ee5122c44969c39071c10cb80f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 Nc9399ad543b94db0ac83399e7f2a6aad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Data Interpretation, Statistical
153 rdf:type schema:DefinedTerm
154 Ncaae9ad919e2419d8894824462b4756b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 Ncaf94963d6e740b1b8c73656ce426a33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Aged, 80 and over
159 rdf:type schema:DefinedTerm
160 Ncd3ed2a5724845bdbc7de1d86ea49297 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Antimetabolites, Antineoplastic
162 rdf:type schema:DefinedTerm
163 Nd1656ab55ed84f9ebc17ad2214b927f4 schema:name nlm_unique_id
164 schema:value 8603469
165 rdf:type schema:PropertyValue
166 Nd167133647f347268b302118b18ca00d schema:name pubmed_id
167 schema:value 11233839
168 rdf:type schema:PropertyValue
169 Nd946b48249b549738ecc10167360e6be rdf:first sg:person.01316171657.10
170 rdf:rest N52b9be1eb3434f8d98eb9f840b05853c
171 Ne531c7481bf144b8bf8c968377fa10d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Antineoplastic Combined Chemotherapy Protocols
173 rdf:type schema:DefinedTerm
174 Ne6ba15ef6a0d4ddba8ce6bcb3469a26d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antineoplastic Agents
176 rdf:type schema:DefinedTerm
177 Ne86029b3c0204765b05b540ba1dfde9b schema:volumeNumber 177
178 rdf:type schema:PublicationVolume
179 Neb8a978c44e945549ee56e689b6504ab schema:name dimensions_id
180 schema:value pub.1025911325
181 rdf:type schema:PropertyValue
182 Nec9bd765c6a04a23b7de073bd7343a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Prognosis
184 rdf:type schema:DefinedTerm
185 Nf552be9de9854b3a8f26462e3aab38fe schema:issueNumber 2
186 rdf:type schema:PublicationIssue
187 Nfc777a5305b14aac93d4fe3e4989fd0a schema:name doi
188 schema:value 10.1007/pl00002387
189 rdf:type schema:PropertyValue
190 Nfcfa0d2443f447c283b6c8220ba91249 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Survival Analysis
192 rdf:type schema:DefinedTerm
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
197 schema:name Oncology and Carcinogenesis
198 rdf:type schema:DefinedTerm
199 sg:journal.1054450 schema:issn 0179-7158
200 1439-099X
201 schema:name Strahlentherapie und Onkologie
202 rdf:type schema:Periodical
203 sg:person.01013257674.45 schema:affiliation https://www.grid.ac/institutes/grid.9018.0
204 schema:familyName Dunst
205 schema:givenName Jürgen
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013257674.45
207 rdf:type schema:Person
208 sg:person.01051147475.66 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
209 schema:familyName Schrott
210 schema:givenName Karl Michael
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051147475.66
212 rdf:type schema:Person
213 sg:person.01110566562.10 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
214 schema:familyName Rödel
215 schema:givenName Claus
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110566562.10
217 rdf:type schema:Person
218 sg:person.01316171657.10 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
219 schema:familyName Grabenbauer
220 schema:givenName Gerhard G.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316171657.10
222 rdf:type schema:Person
223 sg:person.014202704312.23 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
224 schema:familyName Kühn
225 schema:givenName Reinhard
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014202704312.23
227 rdf:type schema:Person
228 sg:person.0621421301.50 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
229 schema:familyName Papadopoulos
230 schema:givenName Thomas
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621421301.50
232 rdf:type schema:Person
233 sg:person.0722130722.52 schema:affiliation https://www.grid.ac/institutes/grid.5330.5
234 schema:familyName Sauer
235 schema:givenName Rolf
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722130722.52
237 rdf:type schema:Person
238 sg:pub.10.1007/bf02742341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014516874
239 https://doi.org/10.1007/bf02742341
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/0360-3016(94)90003-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019330456
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/0959-8049(94)90113-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018946764
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s0022-5347(01)65458-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047312681
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s0022-5347(01)65673-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036005084
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s0022-5347(01)66692-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021146825
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/s0022-5347(01)67321-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014467598
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s0022-5347(05)68208-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013140297
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/s0022-5347(05)68645-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021384730
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/s0022-5347(17)36724-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076835047
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/s0022-5347(17)37241-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077377706
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/s0360-3016(97)00579-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032625558
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/s0360-3016(98)00013-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053656241
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1046/j.1464-410x.1996.08486.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031490175
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1046/j.1464-410x.1997.00431.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008241807
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1093/jnci/85.1.53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059817898
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1159/000472824 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079740078
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.1993.11.11.2150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082711800
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.1995.13.6.1404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082492504
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.1996.14.11.2901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082998128
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.1997.15.3.1022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057217
280 rdf:type schema:CreativeWork
281 https://www.grid.ac/institutes/grid.5330.5 schema:alternateName University of Erlangen-Nuremberg
282 schema:name Department of Pathology, University of Erlangen, Germany, DE
283 Department of Radiation Oncology, University of Erlangen, Germany, DE
284 Department of Urology, University of Erlangen, Germany, DE
285 rdf:type schema:Organization
286 https://www.grid.ac/institutes/grid.9018.0 schema:alternateName Martin Luther University Halle-Wittenberg
287 schema:name Department of Radiation Oncology, University of Halle, Germany, DE
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...